Previous close | 6.47 |
Open | 6.48 |
Bid | 6.46 x 1200 |
Ask | 6.47 x 1100 |
Day's range | 6.45 - 6.53 |
52-week range | 5.31 - 7.26 |
Volume | |
Avg. volume | 783,604 |
Market cap | 700.43M |
Beta (5Y monthly) | 1.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.27 |
Earnings date | 01 May 2024 |
Forward dividend & yield | 0.24 (3.71%) |
Ex-dividend date | 14 Feb 2024 |
1y target est | 7.75 |
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 1, 2024, after the market closes.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the signing of an agreement with the Hebrew University, which facilitate Innocan to initiate the Food and Drug Administration (FDA) approval process for its liposome CBD platform (LPT-CBD) in accordance with FDA's Chemistry Manufacturing Control (CDC) Guidelin
Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 7,952,840 Units at a price of $0.25 per Unit (the "Offering Price") for aggregate gross proceeds of $1,988,210.